ABEO Abeona Therapeutics: Utang marang Ekuitas

Abeona Therapeutics (ABEO) is developing a cell therapy system for severe dermatological pathologies, integrating its innovations into surgical practice. The company is currently focusing on final FDA approval of the innovative drug pz-cel for commercial launch. The business relies on absolute resilience to economic crises, as demand for orphan drugs is independent of the cycle. This chart of the total debt-to-equity ratio is at 0.15.

The indicator's dynamics depend directly on the balance between operating expenses and the volume of funds raised. This metric measures the share of debt capital within the financing structure, determining the issuer's degree of financial autonomy. For Abeona Therapeutics (ABEO), with its capital-intensive production of cell therapies, the risk of over-leverage is amplified by a high base of fixed costs. Investors should evaluate the debt-to-equity ratio as an indicator of stability leading up to the commercialization stage.